NeuroMetrix announced that Synovation Medical Group will conduct an evaluation of Quell wearable pain relief rechnology in fibromyalgia patients.
"We have seen both clinical data and positive reviews that suggest that Quell may be beneficial in reducing pain and improving the quality of life in people who suffer from fibromyalgia," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix.
"This clinical evaluation will provide additional evidence for fibromyalgia patients and their healthcare providers who are considering Quell as a pain relief option."
"Clinical research on innovative therapies is an integral part of what we do," said Kunal Gogna, M.D., of Synovation Medical Group. "We are excited to test the Quell technology and potentially add it to our multidisciplinary approach to pain management.”
Led by Mauro Zappaterra, M.D., Ph.D., Director of Clinical Research, and by Dr. Gogna, Synovation Medical Group supports the use of medical devices as viable alternatives to medication for the treatment of various chronic pain ailments
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription
In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can start, stop, and adjust therapy discreetly via the optional Quell Relief app.
Quell also offers advanced sleep tracking that provides feedback on eight dimensions of sleep including sleep duration, quality, body position, time out of bed, and repetitive leg movements throughout the night.